BLUE Stock Plunges on Update
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
Daily12d
Ursodeoxycholic acid may Reduce need of Cholecystectomy for gallstones after laparoscopic sleeve gastrectomy: Study
Reduce the need for Cholecystectomy for gallstones after laparoscopic sleeve gastrectomy suggests a study published in the BMC Surgery.In this study, we aimed ...
WebMD29d
Livdelzi: A New Treatment Option for Primary Biliary Cholangitis
Livdelzi is usually taken together with another medicine for PBC called ursodeoxycholic acid (also called ursodiol or urso). Livdelzi was studied in 193 people with PBC. The people in the ...
The Pharma Letter5d
Seladelpar wins conditional EC approval for rare liver disease
Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...
Here's why Shilpa Medicare share price jumped 8% in trade on February 13
The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...
India Infoline13d
Shilpa Medicare Gets CDSCO Nod for NAFLD Drug
The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...